MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and data management groups (CERC, Paris, France, Cardialysis, Rotterdam, The Netherlands, CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).
in patient treated with Ultimaster and Ultimaster Tansei DES
4,579 patients, 140 hospitals, 30 countries
All-comers trial in HBR patients after PCI
Discontinuation of DAPT 1 month after the implantation of an Ultimaster™ family DES was non-inferior to the continuation of DAPT for ≥2 additional months with regard to net adverse clinical events and major adverse cardiac or cerebral events. Furthermore, abbreviated DAPT was superior to standard-therapy DAPT with regards to major or clinically relevant nonmajor bleeding.
See the full results on Total Population
Discover the full results for the other subgroups recently published.
Discover our clinical evidence and case studies concerning this topic.
Featured product: Ultimaster™ Sirolimus Eluting Coronary Stent System
Featured products: Ultimaster™ Sirolimus Eluting Coronary Stent System, Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System
500 STEMI patients, randomised 1:3 vs Kaname BMS, primary endpoint TVF 12M. Published and completed
of high bleeding risk patients post bioresorbable polymer coated
with an abbReviated
versus standard DAPT
Featured product: Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System
Mauris sed purus volutpat, convallis nibh ac, feugiat lorem. Sed dignissim arcu eulala.
Our sales representatives are here for you.
Thank you for contacting us!
We typically respond within 2 business days and will come back to you as soon as possible.
This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public
For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.